Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of MORAb-202 versus investigator's choice chemotherapy in platinum-resistant high-grade serous ovarian, primary peritoneal, or fallopian tube cancer
MOH_2023-03-01_012335Phase 2Not yet recruiting
- Sponsor
- : Bristol-Myers Squibb Company
- Start
- Feb 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of farletuzumab ecteribulin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (3 arms), sponsored by : Bristol-Myers Squibb Company. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
farletuzumab ecteribulin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on MOH_2023-03-01_012335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-01_012335.